Related Experiment Video

Updated: May 9, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study

Rebecca P Gelber1, G Webster Ross, Helen Petrovitch

  • 1VA Pacific Islands Health Care System, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA. rebecca.gelber@va.gov

Neurology
|August 6, 2013
PubMed

Insights

Beta-blocker use was linked to a reduced risk of cognitive impairment in elderly hypertensive men. This finding suggests a potential protective effect of beta-blockers against cognitive decline in this population.

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Neurology

Background:

  • Hypertension is a significant risk factor for cognitive impairment in the elderly.
  • Understanding the impact of antihypertensive medications on cognitive health is crucial for geriatric care.

Purpose of the Study:

  • To investigate the association between different classes of antihypertensive medications and the risk of cognitive impairment in elderly hypertensive men.

Main Methods:

  • Prospective community-based cohort study (Honolulu-Asia Aging Study) of 2,197 Japanese American men.
  • Participants with hypertension but no baseline cognitive impairment were followed for cognitive function using the Cognitive Abilities Screening Instrument (CASI).
  • Cognitive impairment was defined as a CASI score <74, with 854 men developing impairment over a median follow-up of 5.8 years.

Main Results:

  • Beta-blocker monotherapy was associated with a significantly lower risk of cognitive impairment (IRR 0.69; 95% CI 0.50-0.94) compared to no antihypertensive medication.
  • No significant associations were found for diuretics, calcium channel blockers, ACE inhibitors, or vasodilators used alone.
  • The protective association of beta-blockers was more pronounced in men with diabetes, those over 75 years, and individuals with higher pulse pressure.

Conclusions:

  • Beta-blocker use is associated with a reduced risk of developing cognitive impairment in elderly hypertensive Japanese American men.
  • These findings highlight the potential neuroprotective role of beta-blockers in managing hypertension-related cognitive decline.
Abstract

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...